Patents by Inventor Jeremy Caldwell

Jeremy Caldwell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210300927
    Abstract: The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
    Type: Application
    Filed: April 7, 2021
    Publication date: September 30, 2021
    Applicant: ARDELYX, INC.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • Patent number: 11091482
    Abstract: The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: August 17, 2021
    Assignee: ARDELYX, INC.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • Patent number: 10968246
    Abstract: The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2?, R3, R4, X1, X2, X3, X4, Q, and n are described herein.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: April 6, 2021
    Assignee: Ardelyx, Inc.
    Inventors: Jason G. Lewis, Michael Robert Leadbetter, Jeremy Caldwell, Dean Dragoli, Noah Bell, Jeffrey W. Jacobs, Patricia Finn, Rakesh Jain, Tao Chen, Matthew Siegel
  • Publication number: 20210017177
    Abstract: The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, A, X1, X2, R1, R2, and R3 are described herein.
    Type: Application
    Filed: August 11, 2020
    Publication date: January 21, 2021
    Applicant: ARDELYX, INC.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • Patent number: 10793568
    Abstract: The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: October 6, 2020
    Assignee: ARDELYX, INC.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • Publication number: 20200062795
    Abstract: The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2?, R3, R4, X1, X2, X3, X4, Q, and n are described herein.
    Type: Application
    Filed: June 28, 2019
    Publication date: February 27, 2020
    Applicant: Ardelyx, Inc.
    Inventors: Jason G. Lewis, Michael Robert Leadbetter, Jeremy Caldwell, Dean Dragoli, Noah Bell, Jeffrey W. Jacobs, Patricia Finn, Rakesh Jain, Tao Chen, Matthew Siegel
  • Publication number: 20190308973
    Abstract: The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
    Type: Application
    Filed: August 23, 2017
    Publication date: October 10, 2019
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • Patent number: 10392413
    Abstract: The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2?, R3, R4, X1, X2, X3, X4, Q, and n are described herein.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: August 27, 2019
    Assignee: ARDELYX, INC.
    Inventors: Jason Gustaf Lewis, Michael Robert Leadbetter, Jeremy Caldwell, Dean Dragoli, Noah Bell, Jeffrey W. Jacobs, Patricia Finn, Rakesh Jain, Tao Chen, Matthew Siegel
  • Publication number: 20190233420
    Abstract: The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.
    Type: Application
    Filed: August 23, 2017
    Publication date: August 1, 2019
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • Publication number: 20170174718
    Abstract: The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2?, R3, R4, X1, X2, X3, X4, Q, and n are described herein.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 22, 2017
    Inventors: Jason Gustaf LEWIS, Michael Robert LEADBETTER, Jeremy CALDWELL, Dean DRAGOLI, Noah BELL, Jeffrey W. JACOBS, Patricia FINN, Rakesh JAIN, Tao CHEN, Matthew SIEGEL
  • Publication number: 20100041732
    Abstract: This invention provides novel methods for identifying agents that inhibit HIV infection. The anti-HIV agents are identified by screening test compounds for ability to down-regulate the kinase activity or the expression of a PAK3 molecule. Such PAK3 modulators can be further examined for their activity in inhibiting HIV infection. These novel anti-HIV agents are useful in the prevention or treatment of HIV infection and conditions associated with HIV infection.
    Type: Application
    Filed: February 6, 2006
    Publication date: February 18, 2010
    Applicant: IRM LLC
    Inventors: Jeremy Caldwell, Deborah Nguyen, Kelly Kuhen
  • Patent number: 7413908
    Abstract: A gel extraction device comprising a hollow cutting member having a cutting edge at one end and a squeeze bulb at the other end. In a further embodiment, the air passage between the cutting edge and the bulb has a constriction zone to prevent any extracted gel from being drawn too deeply into the extractor. In a further embodiment, a blow-hole in the hollow cutting member or in the squeeze bulb provides for the passage of air displaced by gel through the extractor. The blow-hole may be covered to secure the gel in the receptacle for transfer from the matrix to a sample container.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: August 19, 2008
    Inventors: Jeremy Caldwell, Dale Caldwell, Leon Clouser
  • Publication number: 20060286036
    Abstract: This invention provides novel methods for identifying agents that inhibit HIV infection. The anti-HIV agents are identified by screening test compounds for ability to modulate a biological activity of isopeptidase T (IsoT), e.g., its isopeptidase activity or its binding to another molecule such as viral protein R (Vpr). Such IsoT modulators can be further examined for their activity in inhibiting an activity indicative of HIV infection or HIV replication. These novel anti-HIV agents are useful in the prevention or treatment of HIV infection and conditions associated with or caused by HIV infection.
    Type: Application
    Filed: April 21, 2006
    Publication date: December 21, 2006
    Applicant: IRM LLC
    Inventors: Kelli Kuhen, Jeremy Caldwell
  • Publication number: 20060257999
    Abstract: High throughput compound profiling systems, and related devices and sub-systems that can be used to perform various compound profiling processes are provided. These systems typically include work perimeters that are organized for optimum efficiency and processing accuracy. Further, these systems are readily adaptable for performing a wide array of assays, as many different system components are easily incorporated or interchangeable in a particular system. System components that are provided by the invention include cell culture dissociators, which can be used, e.g., to effect cell wetting, dissociation, and/or agitation applications. In some embodiments, these cell culture dissociators are included as components of automated cell culture passaging stations. Dispensing devices that permit on-the-fly fluid temperature regulation are also provided. In addition, various compound profiling methods, cell dissociation methods, uniform cell concentration dispensing methods, among other processes, are also provided.
    Type: Application
    Filed: March 22, 2006
    Publication date: November 16, 2006
    Inventors: Jim Chang, James Mainquist, Robert Downs, Jeremy Caldwell, Frederick King
  • Publication number: 20060171923
    Abstract: This invention relates to the discovery that the transcription factors Pbx1 and HMG1 are involved in retrovirus, e.g., HIV, replication. Thus, the invention provides methods of identifying modulators of these proteins. Such modulators can be used as reagents in in vitro assays to modulate expression of retroviral sequences and may be used to inhibit HIV replication in vivo.
    Type: Application
    Filed: May 18, 2004
    Publication date: August 3, 2006
    Applicant: IRM LLC, a Delaware Limited Liability Company
    Inventors: Sheng Chao, Jeremy Caldwell
  • Publication number: 20060099114
    Abstract: A gel extraction device comprising a hollow cutting member having a cutting edge at one end and a squeeze bulb at the other end. In a further embodiment, the air passage between the cutting edge and the bulb has a constriction zone to prevent any extracted gel from being drawn too deeply into the extractor. In a further embodiment, a blow-hole in the hollow cutting member or in the squeeze bulb provides for the passage of air displaced by gel through the extractor. The blow-hole may be covered to secure the gel in the receptacle for transfer from the matrix to a sample container.
    Type: Application
    Filed: December 20, 2005
    Publication date: May 11, 2006
    Inventors: Jeremy Caldwell, Dale Caldwell, Leon Clouser
  • Publication number: 20060035214
    Abstract: This invention provides methods of screening for compounds that inhibit herpesviral transcription and replication. The methods comprise screening test compounds for ability to enhance the activity of homeodomain transcription factor SATB1 or CDP in repressing transcription of herpesviral genes (e.g., the IE gene of cytomegalovirus). Transcriptional repression by SATB1 or CDP can be monitored using an expression vector comprising a reporter gene operably linked to an SATB1/CDP-binding transcription regulatory sequence of the herpesvirus. The invention further provides methods and pharmaceutical compositions for stimulating SATB1 or CDP-mediated transcriptional repression in a subject and for treating diseases and conditions associated with herpesviral infection.
    Type: Application
    Filed: April 26, 2005
    Publication date: February 16, 2006
    Applicant: IRM LLC, a Delaware Limited Liability Company
    Inventors: Sheng-Hao Chao, Jeremy Caldwell
  • Publication number: 20050281709
    Abstract: A gel extraction device comprising a hollow cutting member and a plunger ejector member. The hollow cutting member has a proximal tubular body terminating at one end in a circular rim having oppositely disposed spring engaging structures and a distal sloped transition portion ending in a rectangular receptacle and a tapered end portion with a sharp perimeter cutting edge. The plunger ejector member has a proximal cap atop and connected to a split stem portion having outer legs with shoulder stop extensions; an inner ribbon spring leg having a distal end inserted into a spring engaging structure in the assembled device; and a solid rectangular distal portion. In a second embodiment the split end portion is replaced by a stem having a plurality of lateral protrusions and a coiled spring is placed within the hollow cutting member tubular body. A third embodiment is a hybrid of the first two embodiments.
    Type: Application
    Filed: June 21, 2004
    Publication date: December 22, 2005
    Inventors: Jeremy Caldwell, Dale Caldwell, Leon Clouser
  • Publication number: 20050058991
    Abstract: This invention provides methods of screening for compounds that inhibit herpesviral transcription and replication. The methods comprise screening test compounds for ability to enhance the activity of homeodomain transcription factor PDX1 in repressing transcription of herpesviral genes (e.g., the IE gene of cytomegalovirus). Transcriptional repression by PDX1 can be monitored using an expression vector comprising a reporter gene operably linked to a PDX1-binding, upstream transcription regulatory sequence of the herpesvirus. The invention further provides methods and pharmaceutical compositions for stimulating PDX1-mediated transcriptional repression in a subject and for treating diseases and conditions associated with herpesviral infection.
    Type: Application
    Filed: July 7, 2004
    Publication date: March 17, 2005
    Applicant: IRM LLC, a Delaware Limited Liability Company
    Inventors: Sheng-Hao Chao, Jeremy Caldwell
  • Publication number: 20050048585
    Abstract: This invention provides novel NF-AT-modulatory polypeptides. The invention also provides methods for screening modulators of NF-AT. The methods comprise first screening test agents for modulators of an NF-AT-modulatory polypeptide and then further screening the identified modulating agents for modulators of NF-AT. The invention further provides methods and pharmaceutical compositions for modulating NF-AT bioactivities in a cell and for treating diseases and conditions mediated by abnormal NF-AT activities.
    Type: Application
    Filed: December 10, 2003
    Publication date: March 3, 2005
    Applicant: IRM LLC, a Delaware Limited Liability Company
    Inventors: Suhaila White, Sumit Chanda, Jeremy Caldwell